Added value of co-morbidity in predicting health-related quality of life in COPD patients  by VAN MANEN, J.G. et al.
Added value of co-morbidity in predicting
health-related quality of life in COPD patients
J. G. VAN MANEN*, P. J. E. BINDELS*, F. W. DEKKER{, C. J. IJZERMANS*, B. J. A. M. BOTTEMA{,
J. S. VAN DER ZEE} AND E. SCHADE´*
*Department of General Practice, Division of Public Health, Academic Medical Center, University of Amsterdam;
{Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam;
{Department of General Practice and Social Medicine, University of Nijmegen and }Department of Pulmonology,
Academic Medical Center, University of Amsterdam, The Netherlands
The extent to which a chronic obstructive pulmonary disease (COPD) patient is impaired in health-related quality
of life (HRQoL) is only to a small extent reflected in clinical and demographical measures. As the influence of co-
morbidity on HRQoL is less clear, we investigated the added value of 23 common diseases in predicting HRQoL in
COPD patients with mild to severe airways obstruction.
COPD patients from general practice who appeared to have an forced expiratory volume in 1 sec/inspiratory
vital capacity (FEV1/IVC)5 predicted71?64 SD, FEV1580% predicted, FEV1 reversibility512% and a smoking
history, were included (n163). HRQoL was assessed with the short-form-36 (SF-36) and the presence of co-
morbidity was determined by a questionnaire, which asked for 23 common diseases.
All domains of the SF-36 were best predicted by the presence of three or more co-morbid diseases. FEV1 %
predicted, dyspnoea and the presence of one or two diseases were second-best predictors. Co-morbidity explained
an additional part of the variance in HRQoL, particularly for emotional functioning (DR20?11). When individual
diseases were investigated, only insomnia appeared to be related to HRQoL.
As HRQoL is still only partly explained, co-morbidity and other patient characteristics do not clearly distinguish
between COPD patients with severe impairments in HRQoL and COPD patients with minor or no impairments in
HRQoL. Therefore, it remains important to ask for problems in daily functioning and well-being, rather than to
rely on patient characteristics alone.
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Previous studies have shown that health-related quality of
life (HRQoL) of COPD patients may be seriously impaired
(1–10). These impairments in HRQoL not only affect
physical functioning, but also emotional and social
functioning. Determinants of HRQoL are, however, less
understood. Lung function parameters, which objectively
indicate the stage of the disease and which are good
predictors of prognosis and survival, are only weakly
related to HRQoL (1,2,4,8–20). Dyspnoea, a more sub-Received 30 August 2000 and accepted in revised form 12 March
2001.
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correlate better with HRQoL than pulmonary function
tests (9–13,19,21). Nevertheless, HRQoL remains largely
unexplained by these determinants. Furthermore, demo-
graphical characteristics such as age, gender and socio-
economic status are weakly or not related to HRQoL
(1,2,8,13,14,17–20,22,23). Therefore, the extent to which a
COPD patient is impaired in daily life and functioning is
only to a small extent reflected in parameters which are
commonly measured in clinical practice.
In previous studies on HRQoL in COPD patients, the
predictive value of co-morbidity on HRQoL has not been
investigated (1–23). Nevertheless, co-morbidity may fre-
quently occur in COPD patients and it may be assumed
that co-morbidity has a substantial impact on HRQoL. To
investigate whether COPD patients with an impaired
HRQoL can be identified by the presence of co-morbidity,
we studied the added value of co-morbidity in predicting
HRQoL in COPD patients. We analysed the influence of 23# 2001 HARCOURT PUBLISHERS LTD
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demographical parameters, on HRQoL in a population of
COPD patients with mild to severe airways obstruction.
Materials and methods
SELECTION OF COPD PATIENTS
Twenty-eight general practices from urban and suburban
regions in the western part of The Netherlands participated
in the study. These practices covered almost 55 000 patients
at the time of study. Selection of patients was carried out in
four steps: (a) all patients who were registered with a
diagnosis of asthma or COPD in their general practice and
who were 40 years or older were selected; (b) the general
practitioners were then asked to exclude patients who met
the following criteria: poor cognitive functioning (n47), a
poor mastering of the Dutch language (n46) and presence
of an end-stage disease (n33); (c) 1106 patients were
eligible, of whom 659 were willing to participate (60%
response); (d) to include patients with COPD only, patients
with an forced expiratory volume in 1 sec/inspiratory vital
capacity (FEV1/IVC) ratio before and after inhalation of
400 mg salbutamol below the reference ratio 71?646SD
[according to the calculation of the lower 5th percentile of
reference values, recommended by the European Respira-
tory Society (24)], FEV1580% predicted, FEV1 reversi-
bility 512% of predicted and a history of smoking were
included (n163). The study was approved by the Medical
Ethics Committee of the Academic Medical Center,
University of Amsterdam.
DATA COLLECTION PROCEDURES
In this study, the term HRQoL refers to physical, social and
emotional aspects of life that may be impaired due to
disease. These aspects include functional status and general
health perceptions according to the model of HRQoL of
Wilson and Cleary (25). Generic HRQoL was measured
instead of disease-specific HRQoL, because disease-specific
instruments, in contrast to generic instruments, are
designed to detect aspects of one particular disease and
might therefore not able to detect aspects of co-morbid
diseases.
HRQoL was determined by the short-form- 36 (SF-36), a
generic measure which is broadly used and validated (26).
The questionnaire is composed of 36 questions, organized
into eight multi-item domains: physical functioning, role
limitations due to physical health problems, social func-
tioning, mental health, role limitations due to emotional
problems, vitality, bodily pain and general health. All raw
domain scores are linearly converted to a 0–100 scale, with
higher scores indicating a better HRQoL.
To determine the presence of diseases, patients were
asked to complete a questionnaire on 23 diseases. This
questionnaire is developed by the Statistics Netherlands (a
government institution which conducts yearly surveys to
collect information on the Dutch society on various topics
among which indicators of health) and is broadly used indemographical studies in The Netherlands (27). Diseases
included in the questionnaire had a prevalence of more than
2% in the general population and were long-lasting by
nature. In the questionnaire, patients were asked whether
they were suffering from each of the 23 diseases at that
moment. Diseases were described so as to be under-
standable for patients. For example, the term ‘high blood
pressure’ was used instead of ‘hypertension’. The following
diseases were asked for: locomotive diseases (rheumatoid
arthritis, arthrosis, slipped disc, disorder of the back for43
months), hypertension, insomnia, serious heart diseases or
myocardial infarction, sinusitis, migraine, depression,
dizziness with falling, ulcer of the stomach/duodenum,
cancer, atherosclerosis, thyroid diseases, diabetes, serious
intestinal diseases for43 months, serious skin diseases, gall
bladder diseases, stroke, chronic cystitis, kidney stones,
thrombosis, epilepsy, liver diseases and renal diseases.
In addition, questions were asked on gender, age, highest
form of education received, coughing (usually at day/night
or daily at least 3 months a year), phlegm (usually at day/
night or daily at least 3 months a year), dyspnoea (when
walking at normal pace on flat ground or when going
upstairs), and smoking (smoking status, number of years
smoked, number of cigarettes smoked per day). Lung
function impairment was assessed by spirometry before and
after inhalation of 400mg salbutamol using a pneumotach
(MasterScope, Jaeger, Germany) according to the Eur-
opean Respiratory Society guidelines for measurement (24),
and carried out by trained personnel.
ANALYSIS
In the questionnaire all participants were asked about the
highest form of education they received (seven levels). The
percentage of patients with a high and a low education was
calculated. We defined a lower level of education as:
primary school, lower vocational training, school for lower
general secondary education (4 years education). The high
educational level was defined as: high general secondary
education (5 or 6 years education), high vocational training
or university. The number of pack-years was calculated
with the following formula: (number of cigarettes smoked
per day6number of years smoked)/20. Fourteen persons
did not answer all 23 questions on chronic diseases.
Therefore, the presence of one or more chronic diseases
(co-morbidity) was calculated only for those persons who
filled in all questions on the existence of chronic diseases.
t-tests were carried out to test whether patients with and
without co-morbidity differed on each domain of the SF-36.
A linear regression analysis was carried out for each
domain to determine the predictive value of co-morbidity
together with other clinical and demographic parameters on
HRQoL. In the linear regression models the SF-36 domain
was the dependent variable. These analyses were carried out
in two steps. First, the independent variables introduced
were age, gender, education, number of pack-years, cough,
phlegm, dyspnoea and FEV1 % predicted. Second, co-
morbid diseases were added as independent variables to the
model to study the added value of co-morbidity in
TABLE 1. General characteristics of the study population.
Data are expressed as numbers (%) or means (SD)*
n163
Mean age (SD) 66?8 (9?8)
Male 117 (71?8)
Low education 138 (86?3)
Mean number of pack-years
(SD)
35?9 (25?3)
FEV1550% predicted 60 (36?8)
FEV1 50–70% predicted 65 (39?9)
FEV1 70–80% predicted 38 (23?3)
Mean % reversibility FEV1
(SD)
5?1 (4?0)
Chronic cough 108 (67?5)
Chronic phlegm 110 (68?8)
Dyspnoea 127 (78?4)
Co-morbidity{ 107 (72?3)








Locomotive diseases 61 (37?9)
Hypertension 32 (20?1)
Heart diseases 25 (15?5)
Insomnia 20 (12?3)
Ulcus stomach/duodenum 16 (9?8)
Sinusitis 15 (9?2)
Cancer 14 (8?6)





Skin diseases 6 (3?7)
Atherosclerosis 6 (3?7)
Kidney stones 6 (3?7)
Serious intestinal diseases 6 (3?7)
Thyroid diseases 4 (2?5)
Cystitis 3 (1?9)
Gallbladder diseases 3 (1?8)
Thrombosis 3 (1?8)
Liver diseases 1 (0?6)
Renal diseases 1 (0?6)
Epilepsy 1 (0?6)
*For variables with missing data, the percentages or means
are based on patients without missing data.
{The presence of co-morbidity and the number of co-
morbid diseases was only calculated for patients who filled
in the complete questionnaire on co-morbidity.
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different ways. First, the number of co-morbid diseases was
added and second, the eight most common individual
diseases were added step-wise forward. To check whether
necessary assumptions in multiple regression were not
violated, normal plots of the residuals of the regression
models were produced. All analyses were carried out using
SPSS 8?0?2 for Windows.
Results
INCLUSION
Of the 1106 eligible patients with a known diagnosis of
asthma or COPD, 659 were willing to participate (60%).
The percentage of men was not significantly different
between non-participants (43%) and participants (49%),
but there was a significant difference in age between non-
partcipants (66 years, SD15) and participants (62 years,
SD13). Of the participants, 163 (25%) were found to have
a persistent airway obstruction, a reversibility in FEV1 %
predicted less than 12% and a history of smoking. They
fulfilled our criteria for COPD and were included in the
analyses. Patients who were excluded on the basis of these
criteria and who were thus not considered COPD patients,
were less often men (41 vs. 72% men) and were younger [61
(SD12) vs. 67 (SD10)] than those who were included.
GENERAL CHARACTERISTICS
In Table 1, the general characteristics of COPD patients in
this study are presented. As can be seen, the mean age was
67 years, 72% of the patients were male, the majority had a
low education (86%) and the mean number of pack-years
was 36. Most patients had a moderate (FEV1 50–70%
predicted) (40%) or severe (FEV1550% predicted) (37%)
airways obstruction and the mean per cent reversibility of
FEV1 was 5?1. The majority of patients reported symptoms
of airway disease. Dyspnoea was the most frequently
mentioned symptom (78%).
Seventy-two per cent of the patients had one or more of
23 co-morbid diseases. Most patients were suffering from
one (31%) or two (22%) diseases, while 20% suffered from
three or more diseases. The ten most frequently mentioned
diseases were: locomotive diseases (38%), hypertension
(20%), heart diseases (16%), insomnia (12%), ulcer of the
stomach/duodenum (10%), sinusitis (9%), cancer (9%),
dizziness with falling (7%), migraine (6%) and stroke (6%).
CO-MORBIDITY AND HEALTH-RELATED
QUALITY OF LIFE, UNIVARIATE ANALYSIS
Table 2 shows the mean scores on the eight domains of the
SF-36 for patients with different types of co-morbidity.
Each group of COPD patients with co-morbidity was
compared with COPD patients without. Patients with one
or more co-morbid diseases had significantly lower scores
on physical functioning (50 vs. 59), role functioning due to







Mental health Role function
emotional
Vitality Bodily pain General health
No co-morbidity 41 60?0 (20?4) 68?2 (32?7) 83?2 (21?4) 79?3 (13?0) 87?8 (26?6) 61?1 (14?4) 88?8 (18?5) 49?1 (15?9)
1 diseases{ 107 50?0 (26?8)* 48?1 (43?6)* 72?0 (28?7)* 71?2 (20?8)* 67?9 (42?8)* 55?9 (23?4) 83?6 (23?2) 45?8 (20?4)
1–2 diseases{ 78 54?6 (26?6) 55?4 (43?3) 77?2 (28?1) 74?9 (18?9) 74?7 (39?8) 60?5 (22?6) 87?0 (21?1) 49?5 (19?8)
3 diseases{ 29 37?5 (23?5)* 27?7 (38?1)* 57?8 (25?8)* 61?4 (22?7)* 50?6 (46?0)* 43?6 (21?1)* 74?4 (26?2)* 35?8 (18?8)*
Locomotive dis-
eases
61 45?5 (25?9)* 41?3 (43?4)* 70?9 (27?6)* 70?8 (19?7)* 64?4 (43?3)* 52?4 (21?5)* 81?9 (24?6) 43?0 (19?0)
Hypertension 32 53?2 (29?9) 54?8 (46?7) 72?6 (29?5) 74?2 (18?1) 74?2 (41?0) 59?0 (22?1) 87?4 (18?1) 49?3 (16?4)
Heart diseases 25 45?2 (24?8)* 53?3 (46?7) 73?0 (28?3) 72?6 (20?5) 68?1 (42?3)* 56?6 (21?7) 82?0 (25?0) 40?8 (14?3)*
Insomnia 20 41?4 (29?0)* 31?3 (39?6)* 56?3 (29?7)* 54?4 (25?6)* 53?3 (43?8)* 41?0 (21?1)* 70?8 (26?5)* 32?7 (22?3)*
Ulcus duodenum
/stomach
16 50?9 (28?5) 46?7 (46?2) 75?8 (31?8) 73?8 (19?2) 66?7 (43?9) 55?6 (23?9) 85?6 (23?1) 49?4 (22?1)
Sinusitis 15 41?8 (24?9)* 23?1 (40?1)* 72?3 (24?1) 68?6 (23?1) 51?3 (42?2)* 46?1 (18?8)* 67?6 (31?2)* 36?0 (21?2)*
Cancer 14 48?1 (36?0) 44?6 (42?9)* 69?6 (34?6) 71?7 (25?8) 51?3 (46?4)* 61?4 (26?7) 85?4 (23?4) 50?7 (21?2)
Dizziness with
falling
11 33?4 (29?7)* 31?8 (37?2)* 63?6 (33?3) 66?9 (27?0) 60?6 (44?3) 48?6 (23?2)* 80?1 (24?6) 40?0 (18?2)
Migraine 9 55?0 (29?5) 40?6 (46?2) 72?2 (29?8) 67?6 (29?0) 58?3 (42?7) 51?7 (19?5) 67?6 (25?8)* 44?4 (12?4)
Stroke 9 32?8 (27?6)* 41?7 (43?3)* 69?4 (33?7) 76?0 (25?6)* 81?5 (33?8) 53?9 (24?0) 87?5 (19?8) 43?9 (17?6)
*P50?05, reference group is patients without co-morbidity (t-test).











































500 J. G. VAN MANEN ET AL.physical problems (48 vs. 69), social functioning (71 vs. 83),
mental health (71 vs. 80) and role functioning due to
emotional problems (68 vs. 87). Patients with one or two
other diseases were not significantly more impaired on all
domains, while patients with three or more diseases were
significantly more impaired on all domains.
Furthermore, when compared to patients without co-
morbidity, scores on physical functioning were especially
low in patients with dizziness and stroke, while scores on
role functioning due to physical problems, social function-
ing, mental health, role functioning due to emotional
problems, vitality and general health were low in patients
with insomnia. Scores on role functioning due to physical
or emotional problems, vitality, bodily pain and general
health were also low in patients with sinusitis. Scores on
role functioning due to emotional problems and bodily pain
finally appeared to be low in patients with migraine.
CO-MORBIDITY AND HEALTH-RELATED
QUALITY OF LIFE, MULTIVARIATE
ANALYSIS
The multivariate analyses were carried out to study which
diseases were associated with HRQoL independently of
each other and independently of demographical and clinical
characteristics of COPD patients. In Table 3, the results for
the influence of the number of co-morbid diseases on
HRQoL, are presented. The linear regression analyses with
each domain as dependent variable were carried out in two
steps. First, only demographical and clinical characteristics
were related to the domains. Second, the number of co-
morbid diseases was added to this model. As the b of the
first and the second model did not differ greatly, only the b
of the second model are presented.
Table 3 shows that gender was associated with physical
functioning, social functioning, and role functioning due to
emotional problems, indicating that men were less impaired
than women. Age, education and pack-years were not
related to any domain. With respect to the clinical
characteristics, FEV1 was related to physical functioning,
social functioning, vitality and general health. Dyspnoea
was related to physical functioning, role functioning due to
physical problems, mental health and vitality. Chronic
cough and chronic phlegm were not significantly related to
any domain. The presence of one or two diseases was
associated with worse scores on role functioning due to
physical problems, mental health, and role functioning due
to emotional problems. The presence of three or more
diseases was significantly related to all domains.
It appeared that all domains were best predicted by the
presence of three or more co-morbid diseases. Physical
functioning, social functioning and general health were
second best predicted by FEV1 % predicted. Role
functioning due to physical problems and vitality on the
other hand was second-best predicted by dyspnoea. Mental
health and role functioning due to emotional problems
finally were second-best predicted by the presence of one or
two diseases.The demographical and clinical characteristics together
explained 30% of the variance of physical functioning, 16%
of the variance of role functioning due to physical problems
and 14% of the variance of vitality. The proportion of the
variance explained was less for the other domains
(R20?10). When co-morbidity was added to the model,
all R2 increased. The largest increase was noted for mental
health (DR20?11) and role functioning due to emotional
problems (DR20?11).
Instead of the number of co-morbid diseases, we also
added the eight most common individual diseases step-wise
forward to the model with only demographic and clinical
variables (Table 4). In Table 3 all domains were best
predicted by three or more co-morbid diseases. When the
eight most common individual diseases were analysed, it
appeared that only mental health, bodily pain and general
health were best predicted by a co-morbid disease, namely
insomnia. Physical functioning, role functioning due to
physical problems and vitality were on the other hand best
predicted by dyspnoea. Social functioning was best
predicted by gender.
For the models in Table 4, the variance was less
explained for all domains than for the models in Table 3,
except for physical functioning. Nevertheless, the R2 was
higher for all domains than the model with only demo-
graphic and clinical characteristics. The largest increases
were noted for mental health (DR20?11) as a result of
insomnia. Insomnia was related to all domains except role
functioning due to physical problems, and was most
strongly related to mental health. Locomotive diseases,
hypertension, stomach or duodenal ulcers and sinusitis
were not significantly related to any domain.
Discussion
In this study, the relationship between several co-morbid
diseases, together with demographical and clinical char-
acteristics and HRQoL in patients with mild to severe
COPD was investigated. The results of this study indicate
that the presence of three or more co-morbid diseases in
COPD patients was more predictive of HRQoL than any
demographic variable or clinical variable, such as FEV1 or
airway symptoms. FEV1, dyspnoea and the presence of one
or two diseases were second-best predictors of HRQoL.
When the relationships between individual diseases and
HRQoL were investigated, only insomnia appeared to be
significantly related to HRQoL. Co-morbid diseases were
of added value in predicting HRQoL, particularly with
respect to emotional status (mental health and role
functioning due to emotional problems).
Although there was some drop-out in this study, the
COPD patients included in our study had a wide range of
ages and airway obstruction. Furthermore, males and
females, patients with a high and a low education, and
patients with and without respiratory symptoms or co-
morbidity were all represented. The patients in our study
thus represented COPD patients with all relevant char-
acteristics to study the independent influence of these
characteristics on HRQoL.
TABLE 3. Influence of number of co-morbid diseases and other determinants on HRQoL. Linear regression analysis with domain as dependent variable in two steps: model





Social functioning Mental health Role function
emotional
Vitality Bodily pain General health
Standardized b
Age (years) 70?16 0?04 50?01 0?18 0?11 0?05 0?09 0?07
Male gender 0?20* 0?05 0?20* 0?10 0?23* 0?11 0?12 0?08
Low education 70?06 70?05 0?03 70?08 70?01 0?08 0?05 0?02
Number of
pack-years
0?12 0?04 0?04 0?02 50?01 0?07 0?11 0?09
FEV1 %
predicted
0?32* 0?09 0?21* 0?09 0?01 0?20* 0?07 0?30*
Chronic cough 70?02 70?04 70?07 70?03 0?01 70?09 70?07 70?13
Chronic phlegm 0?02 70?05 0?02 0?06 50?01 70?05 0?14 70?05
Dyspnoea 70?32* 70?37* 70?11 70?19* 70?17 70?24* 70?12 70?10
1–2 diseases 70?10 70?24* 70?12 70?22* 70?26 50?01 70?07 70?04








0?37 0?24 0?16 0?15 0?17 0?20 0?07 0?18












































TABLE 4. Influence of eight most common co-morbid diseases{ and other determinants on health-related quality of life among
COPD patients. Linear regression analysis with domain as dependent variable in two steps: model without co-morbidity (only
adjusted R2 is shown) and model with co-morbidity (standardized b as well as adjusted R2 are shown). In the model with co-













Vitality Bodily pain General
health
Standardized b
Age (years) 70?16* 70?03 70?04 0?11 0?06 0?01 0?06 0?06
Male gender 0?21* 0?08 0?25* 0?16 0?26* 0?15 0?16 0?15
Low education 70?08 70?05 70?01 70?10 70?02 0?05 0?03 570?01
Number of pack-years 0?10 0?02 70?04 70?06 70?02 570?01 0?04 0?02
FEV1 % predicted 0?26* 0?05 0?13* 570?01 70?02 0?12 0?01 0?18*
Chronic cough 70?02 70?05 70?09 70?04 70?04 70?10 70?09 70?14
Chronic phlegm 0?03 70?08 70?03 0?01 70?03 70?06 0?10 70?05
Dyspnoea 70?39* 70?44* 70?19* 70?25* 70?20* 70?32* 70?17 70?22*
Heart diseases 70?19*
Insomnia 70?18* 70?22* 70?34* 70?20* 70?27* 70?18* 70?24*
Cancer 70?20*








0?39 — 0?12 0?17 0?13 0?28 0?05 0?17
DR2 0?07 — 0?04 0?11 0?07 0?07 0?02 0?06
*P50?05.
{Eight most common diseases: locomotive diseases, hypertension, heart diseases, insomnia, gastric ulcus, sinusitis, cancer and
dizziness with falling.
502 J. G. VAN MANEN ET AL.In previous studies, dyspnoea appeared to be one of the
best predictors of generic and disease-specific HRQoL.
Pulmonary function tests, particularly FEV1, were asso-
ciated with generic and disease-specific HRQoL, but the
relationships were weak. Our study confirmed these
findings, although the influence of dyspnoea in our study
was less marked when all co-morbid diseases were included
in the multivariate models. Some co-morbid diseases, such
as heart diseases, may also be associated with dyspnoea. As
a result, co-morbidity may have partly removed the effect of
dyspnoea on HRQoL.
As the associations of co-morbidity, dyspnoea and FEV1
with HRQoL were independent of each other, these factors
all provided complementary information about HRQoL of
COPD patients. Co-morbidity, as the best predictor of
HRQoL, provided most information. In one study the
effects of FEV1 and co-morbidity were investigated (9). This
study showed that the influence of co-morbidity on HRQoL
was particularly seen in patients with relative mild airways
obstruction (FEV1450% predicted) and that the influence
of airways obstruction (FEV1) was particularly seen in
patients without co-morbidity. However, the relative con-
tribution of these factors to HRQoL was not presented and
data on the separate domains of HRQoL were not given.
Except for insomnia, we could not identify individual
diseases which were significantly related to HRQoL. As thepresence of three or more diseases was, however, strongly
related to all domains of HRQoL, it is probably the number
of co-morbid diseases, rather than the type of disease, which
cause impairments in HRQoL in COPD patients. However,
this conclusion should be mentioned with some caution. The
absence of relationship between individual diseases and
HRQoL may also be attributed to the relative low number
of patients with these diseases. The influence of the disease on
HRQoL should then be large to detect a significant effect.
Furthermore, we did not investigate the relationship with
HRQoL for the least frequent diseases, although they might
have had a large influence on HRQoL. Renal disease, for
example, only occurred in one patient in our study.
However, as these diseases are infrequent, they are also of
lesser relevance to clinical practice. Finally, some diseases
may have an influence on HRQoL only when they reach a
certain degree of severity. As we did not determine the
severity of co-morbid diseases, we were not able to
investigate this possibility. Furthermore, the influence of
insomnia on HRQoL can also be considered as the
influence of a symptom of COPD rather than the influence
of a co-morbid disease, because insomnia may be a sleep-
related breathing disorder.
The total proportion of variance in HRQoL explained by
all demographical and clinical variables and co-morbidity
ranged from 7% (bodily pain) to 37% (physical function-
CO-MORBIDITY IN PREDICTING QUALITY OF LIFE IN COPD PATIENTS 503ing). Although co-morbidity added 5–11% to the explained
variance, the largest part of the variance in HRQoL is thus
still unexplained. In previous studies the proportion of the
variance in HRQoL explained ranged from 8% to 71%
(1,2,4,8,10,13,16,17,20,22,23). However, these results are
dicult to compare with the results of our study because
in these studies different independent variables were used to
predict HRQoL. Some studies used other independent
variables such as other HRQoL instruments, exercise
tolerance or activities of daily living. We believe these
measures are all part of HRQoL rather than determinants of
HRQL and do therefore not indicate which part of HRQoL
is explained by patient characteristics. Instead, they provide
information on the validity of a HRQoL instrument.
One final limitation of this study needs to be mentioned.
The results of our study were based on a subjective measure
of co-morbidity, namely the self-report of patients. Several
studies have indicated that patients’ self-reports are fairly
accurate (28–30). Moreover, some problems, such as
insomnia, may not be detected otherwise. However, for
some diseases agreement between questionnaire data and
medical record data is rather poor, e.g. in the case of
locomotive diseases (28,29). These diseases may reflect a
symptom rather than a physician-diagnosed disease. The
data on these diseases should therefore be interpreted as
such. Nevertheless, these data are expected to be valid for
assessing the symptom rather than the diagnosis, because
patients are considered to be the best experts in reporting
perceived disease symptoms.
In conclusion, co-morbidity is a better predictor of
HRQoL than demographic variables and clinical variables
which are routinely measured in COPD patients. The
importance of co-morbidity for HRQoL is particularly
relevant as co-morbid diseases frequently occur in COPD
patients. The presence of three or more co-morbidities has a
highly significant impact on HRQoL. Furthermore, in-
somnia deserves special attention, as it is one of the most
frequently mentioned problems (12%) and it has an
important influence on almost all aspects of HRQoL.
Asking about sleeping problems may therefore give
information on the impairments COPD patients experience
in daily life. However, as HRQoL is still only partly
explained, co-morbidity and other patient characteristics do
not clearly distinguish between COPD patients with severe
impairments in HRQoL and COPD patients with minor or
no impairments in HRQoL. Therefore, it remains impor-
tant to ask for problems in daily functioning and well-
being, rather than to rely on patient characteristics alone.
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